drugset
drugset / Trial / NCT04977960

Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19

NCT04977960 ↗

Phase 2 Unknown 180 enrolled Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico IRCCS Azienda Ospedaliero-Universitaria di Bologna · collabUniversity of Milan · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The main aim of the study is to estimate the potential efficacy of i.v. canrenone as add-on therapy on maximal medical treatment versus maximal medical treatment alone in treating moderate-to-severe ARDS due to SARS-CoV-2.

Timeline

Start
2022-09
Primary completion
2023-05
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Canrenoate Small molecule — Intravenous

Indications

acute respiratory distress syndrome